DV
Dividend Vision

NYXH — Nyxoah

Nyxoah (NYXH)

Total return is -93.2% over the past 5.3 years, 192.9 points behind SPY at 99.7%. Its deepest 1-year drawdown was 80.7%.

Nyxoah SA is a Belgian medical technology company that develops and commercializes solutions for treating obstructive sleep apnea, with its primary offering being the Genio system, a hypoglossal neurostimulation therapy. The company does not currently distribute dividends. Nyxoah may appeal to growth-oriented investors seeking exposure to the medical device sector, though investors focused on current income would find no dividend yield here.

NYXH key facts

Asset type
Stock
Asset class
Equity
Inception date
04/28/2021
Last close
$1.62
Market cap
$154,112,128
Average volume
117525.0
Beta
0.963
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.40